TJ0113 clinical trials
Also written TJ0113.
How each study uses TJ0113 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TJ0113 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Hangzhou PhecdaMed Co., Ltd. (5) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Yilai Shu (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test TJ0113.
- Dec 2026A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing LossNot applicable · Yilai Shu
- Aug 2027Clinical Study of TJ0113 Capsule in the Treatment of Patients With SarcopeniaPhase 2 · Hangzhou PhecdaMed Co., Ltd.
Studies
Open first, then newest update. How each study uses TJ0113 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's DiseaseNot yet recruitingPhase 3Hangzhou PhecdaMed Co., Ltd.NCT07741045Written as TJ0113 200mg
- Clinical Study of TJ0113 Capsule in the Treatment of Patients With SarcopeniaRecruitingPhase 2Hangzhou PhecdaMed Co., Ltd.NCT07620938Written as TJ0113
- A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing LossNot yet recruitingNot applicableYilai ShuNCT07012746Written as TJ0113 capsules
- Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive DisorderCompletedPhase 2Hangzhou PhecdaMed Co., Ltd.NCT07018245Written as TJ0113
- Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy SubjectsCompletedPhase 1Hangzhou PhecdaMed Co., Ltd.NCT07394452Written as TJ0113 Capsules
- Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's DiseaseCompletedPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06596005Written as TJ0113 200mg
- Mass Balance Study of [14C] TJ0113 in Healthy Chinese SubjectsCompletedPhase 1Hangzhou PhecdaMed Co., Ltd.NCT06832540Written as [14C]TJ0113